X4 Pharmaceuticals targets 2028 data readout for neutropenia drug

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. REGN
2. LITE
3. CRWD
4. AAPL
5. ABBV
6. MRVL
7. CL
8. TFII
9. ORCL
10. LYB

Go back to X4 Pharmaceuticals targets 2028 data readout for neutropenia drug

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

October 29, 2026 4:30 PM EDT

- Base Case U.S. Market Opportunity Estimated at 15,000 Patients, With Potential to Expand to Approximately 30,000 Patients -

- On Track for Completion of 4WARD Phase 3 Target Enrollment in Q4 2026 -

- Planned 4STEPS Phase 2b Trial Evaluating G-CSF Dose Reduction with Mavorixafor;
Initiation Expected in Q1 2027 -

- Topline Data from Both 4WARD and 4STEPS Expected in Q1 2028 -

BOSTON, Oct. 29, 2026 (GLOBE NEWSWIRE) --... More